Breast cancer is one of the most common cancers with more than 1,300,000 cases and 450,000 deaths each year worldwide. Predicting distant recurrence is difficult to assess using current clinical and histopathological parameters, and no validated serum biomarkers yet exist. Consequently, a number of patients are over and/or non-optimally treated, resulting in side-effects for patients and increased costs for healthcare providers. There is thus a great clinical need for a non-invasive test that allows the risk of recurrence to be predicted.
Histological grading is one of the most commonly used prognostic features. However, current methodologies are associated with significant shortcomings, making clinical decision-making challenging. Hence there is a great clinical need for a non-invasive test enabling improved molecular grading of breast cancer.
Solution provided by Immunovia
Based on IMMray™ we have, in an early discovery study at Lund University defined a condensed panel of serum biomarkers (a biomarker signature) associated with breast cancer. This biomarker panel could potentially be used to predict the development of distant metastases, out-performing current procedures. The test would then be suitable for predicting breast cancer patients for the risk of developing distant recurrence after primary operation.
Immunovia has also, in another early discovery study at Lund University, defined a condensed panel of tumor tissue biomarkers, the biomarker signature, associated with breast cancer. This biomarker panel could potentially be used to improve molecular grading and thereby prognosis in breast cancer, all based on a single, specific and robust assay. The test will be suitable for grading breast cancer patients, in particular those previously defined as grade 2 (30-60% of all patients). This represents a cohort of very heterogeneous tumors and currently available tests are thus less informative for clinical decision-making.
We are in the discovery phase of these tests.